nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CCR5—IL12-mediated signaling events—IL12A—liver cancer	0.0164	0.0561	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCR4—liver cancer	0.0155	0.0528	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—CCR4—liver cancer	0.0124	0.0423	CbGpPWpGaD
Maraviroc—CYP3A4—Felbamate Metabolism—CYP2E1—liver cancer	0.0113	0.0385	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—STAT4—liver cancer	0.0113	0.0385	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL12B—liver cancer	0.0103	0.0352	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CD8A—liver cancer	0.00746	0.0255	CbGpPWpGaD
Maraviroc—CYP3A4—Liver X Receptor Pathway—SCD—liver cancer	0.00678	0.0231	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—MAPK14—liver cancer	0.00604	0.0206	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCR4—liver cancer	0.00583	0.0199	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD8A—liver cancer	0.00539	0.0184	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CCR4—liver cancer	0.00491	0.0168	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.00456	0.0156	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK14—liver cancer	0.00437	0.0149	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—MTOR—liver cancer	0.00429	0.0146	CbGpPWpGaD
Maraviroc—CCR5—Disease—APCS—liver cancer	0.00427	0.0146	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL2—liver cancer	0.00394	0.0135	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.00391	0.0133	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—PSMA4—liver cancer	0.00391	0.0133	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—PSMD10—liver cancer	0.00391	0.0133	CbGpPWpGaD
Maraviroc—CYP3A4—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00374	0.0127	CbGpPWpGaD
Maraviroc—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00367	0.0125	CbGpPWpGaD
Maraviroc—CYP3A4—Farnesoid X Receptor  Pathway—NR1H4—liver cancer	0.00342	0.0117	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—STAT3—liver cancer	0.00332	0.0113	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—RAF1—liver cancer	0.00318	0.0108	CbGpPWpGaD
Maraviroc—CYP3A4—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.00314	0.0107	CbGpPWpGaD
Maraviroc—CYP3A4—Estrogen metabolism—GSTA1—liver cancer	0.00302	0.0103	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCR4—liver cancer	0.00298	0.0102	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—JUN—liver cancer	0.00277	0.00946	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK8—liver cancer	0.00262	0.00895	CbGpPWpGaD
Maraviroc—Herpes zoster—Epirubicin—liver cancer	0.00259	0.00366	CcSEcCtD
Maraviroc—Scotoma—Epirubicin—liver cancer	0.00257	0.00363	CcSEcCtD
Maraviroc—Erythema multiforme—Sorafenib—liver cancer	0.00251	0.00355	CcSEcCtD
Maraviroc—Otitis media—Epirubicin—liver cancer	0.00251	0.00354	CcSEcCtD
Maraviroc—Laryngitis—Doxorubicin—liver cancer	0.0025	0.00354	CcSEcCtD
Maraviroc—Cardiac disorder—Sorafenib—liver cancer	0.00246	0.00348	CcSEcCtD
Maraviroc—Haemoptysis—Doxorubicin—liver cancer	0.00244	0.00345	CcSEcCtD
Maraviroc—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—liver cancer	0.00243	0.0083	CbGpPWpGaD
Maraviroc—Neuritis—Doxorubicin—liver cancer	0.00242	0.00342	CcSEcCtD
Maraviroc—Angiopathy—Sorafenib—liver cancer	0.0024	0.0034	CcSEcCtD
Maraviroc—Herpes zoster—Doxorubicin—liver cancer	0.0024	0.00339	CcSEcCtD
Maraviroc—Mediastinal disorder—Sorafenib—liver cancer	0.00239	0.00338	CcSEcCtD
Maraviroc—Scotoma—Doxorubicin—liver cancer	0.00238	0.00336	CcSEcCtD
Maraviroc—Alopecia—Sorafenib—liver cancer	0.00234	0.00331	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—F2—liver cancer	0.00233	0.00794	CbGpPWpGaD
Maraviroc—Mental disorder—Sorafenib—liver cancer	0.00232	0.00329	CcSEcCtD
Maraviroc—Otitis media—Doxorubicin—liver cancer	0.00232	0.00328	CcSEcCtD
Maraviroc—Erythema—Sorafenib—liver cancer	0.00231	0.00326	CcSEcCtD
Maraviroc—Malnutrition—Sorafenib—liver cancer	0.00231	0.00326	CcSEcCtD
Maraviroc—Neoplasm malignant—Epirubicin—liver cancer	0.00228	0.00323	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CHN2—liver cancer	0.00227	0.00773	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—TGFB1—liver cancer	0.00222	0.00759	CbGpPWpGaD
Maraviroc—Jaundice cholestatic—Epirubicin—liver cancer	0.00222	0.00314	CcSEcCtD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00221	0.00756	CbGpPWpGaD
Maraviroc—Rectal haemorrhage—Epirubicin—liver cancer	0.00216	0.00306	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00215	0.00732	CbGpPWpGaD
Maraviroc—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00215	0.00303	CcSEcCtD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00214	0.00729	CbGpPWpGaD
Maraviroc—Anaemia—Sorafenib—liver cancer	0.00213	0.00302	CcSEcCtD
Maraviroc—Oliguria—Epirubicin—liver cancer	0.00212	0.00299	CcSEcCtD
Maraviroc—Herpes simplex—Epirubicin—liver cancer	0.00212	0.00299	CcSEcCtD
Maraviroc—Neoplasm malignant—Doxorubicin—liver cancer	0.00211	0.00299	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00211	0.0072	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IFT88—liver cancer	0.00207	0.00707	CbGpPWpGaD
Maraviroc—Syncope—Sorafenib—liver cancer	0.00207	0.00293	CcSEcCtD
Maraviroc—Leukopenia—Sorafenib—liver cancer	0.00207	0.00292	CcSEcCtD
Maraviroc—Ulcer—Epirubicin—liver cancer	0.00206	0.00292	CcSEcCtD
Maraviroc—Jaundice cholestatic—Doxorubicin—liver cancer	0.00205	0.00291	CcSEcCtD
Maraviroc—Loss of consciousness—Sorafenib—liver cancer	0.00203	0.00287	CcSEcCtD
Maraviroc—Cough—Sorafenib—liver cancer	0.00201	0.00285	CcSEcCtD
Maraviroc—Inflammation—Epirubicin—liver cancer	0.00201	0.00284	CcSEcCtD
Maraviroc—Rectal haemorrhage—Doxorubicin—liver cancer	0.002	0.00283	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.00198	0.00281	CcSEcCtD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00197	0.00673	CbGpPWpGaD
Maraviroc—Myalgia—Sorafenib—liver cancer	0.00196	0.00278	CcSEcCtD
Maraviroc—Oliguria—Doxorubicin—liver cancer	0.00196	0.00277	CcSEcCtD
Maraviroc—Herpes simplex—Doxorubicin—liver cancer	0.00196	0.00277	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00195	0.00276	CcSEcCtD
Maraviroc—Ulcer—Doxorubicin—liver cancer	0.00191	0.0027	CcSEcCtD
Maraviroc—Influenza like illness—Epirubicin—liver cancer	0.00189	0.00268	CcSEcCtD
Maraviroc—Colitis—Epirubicin—liver cancer	0.00187	0.00265	CcSEcCtD
Maraviroc—Infection—Sorafenib—liver cancer	0.00187	0.00265	CcSEcCtD
Maraviroc—Inflammation—Doxorubicin—liver cancer	0.00186	0.00263	CcSEcCtD
Maraviroc—Shock—Sorafenib—liver cancer	0.00185	0.00262	CcSEcCtD
Maraviroc—Nervous system disorder—Sorafenib—liver cancer	0.00185	0.00261	CcSEcCtD
Maraviroc—Skin disorder—Sorafenib—liver cancer	0.00183	0.00259	CcSEcCtD
Maraviroc—Anorexia—Sorafenib—liver cancer	0.00179	0.00254	CcSEcCtD
Maraviroc—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.00179	0.0061	CbGpPWpGaD
Maraviroc—Neoplasm—Epirubicin—liver cancer	0.00176	0.00249	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—TRIO—liver cancer	0.00175	0.00598	CbGpPWpGaD
Maraviroc—Influenza like illness—Doxorubicin—liver cancer	0.00175	0.00248	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—HRAS—liver cancer	0.00175	0.00597	CbGpPWpGaD
Maraviroc—Colitis—Doxorubicin—liver cancer	0.00173	0.00245	CcSEcCtD
Maraviroc—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.00172	0.00586	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00172	0.00243	CcSEcCtD
Maraviroc—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.00171	0.00583	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCR4—liver cancer	0.00168	0.00574	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—IL6—liver cancer	0.00168	0.00572	CbGpPWpGaD
Maraviroc—CCR5—Disease—LTF—liver cancer	0.00167	0.00569	CbGpPWpGaD
Maraviroc—Lymphadenopathy—Epirubicin—liver cancer	0.00166	0.00235	CcSEcCtD
Maraviroc—Decreased appetite—Sorafenib—liver cancer	0.00164	0.00232	CcSEcCtD
Maraviroc—Neoplasm—Doxorubicin—liver cancer	0.00163	0.00231	CcSEcCtD
Maraviroc—Diabetes mellitus—Epirubicin—liver cancer	0.00163	0.0023	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00163	0.0023	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Sorafenib—liver cancer	0.00163	0.0023	CcSEcCtD
Maraviroc—Fatigue—Sorafenib—liver cancer	0.00162	0.0023	CcSEcCtD
Maraviroc—Constipation—Sorafenib—liver cancer	0.00161	0.00228	CcSEcCtD
Maraviroc—Pain—Sorafenib—liver cancer	0.00161	0.00228	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—TRIO—liver cancer	0.00159	0.00543	CbGpPWpGaD
Maraviroc—Vascular purpura—Epirubicin—liver cancer	0.00158	0.00224	CcSEcCtD
Maraviroc—Eczema—Epirubicin—liver cancer	0.00158	0.00223	CcSEcCtD
Maraviroc—Hepatic failure—Epirubicin—liver cancer	0.00158	0.00223	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00156	0.00533	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—AKT1—liver cancer	0.00155	0.00527	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Sorafenib—liver cancer	0.00154	0.00218	CcSEcCtD
Maraviroc—Lymphadenopathy—Doxorubicin—liver cancer	0.00154	0.00217	CcSEcCtD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.00154	0.00524	CbGpPWpGaD
Maraviroc—Renal failure acute—Epirubicin—liver cancer	0.00153	0.00217	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CCR4—liver cancer	0.00153	0.00521	CbGpPWpGaD
Maraviroc—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00151	0.00213	CcSEcCtD
Maraviroc—Diabetes mellitus—Doxorubicin—liver cancer	0.00151	0.00213	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Epirubicin—liver cancer	0.0015	0.00212	CcSEcCtD
Maraviroc—Body temperature increased—Sorafenib—liver cancer	0.00149	0.00211	CcSEcCtD
Maraviroc—Abdominal pain—Sorafenib—liver cancer	0.00149	0.00211	CcSEcCtD
Maraviroc—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.00147	0.00503	CbGpPWpGaD
Maraviroc—Purpura—Epirubicin—liver cancer	0.00147	0.00208	CcSEcCtD
Maraviroc—Vascular purpura—Doxorubicin—liver cancer	0.00146	0.00207	CcSEcCtD
Maraviroc—Hepatic failure—Doxorubicin—liver cancer	0.00146	0.00206	CcSEcCtD
Maraviroc—Eczema—Doxorubicin—liver cancer	0.00146	0.00206	CcSEcCtD
Maraviroc—Cerebrovascular accident—Epirubicin—liver cancer	0.00144	0.00204	CcSEcCtD
Maraviroc—Renal failure acute—Doxorubicin—liver cancer	0.00142	0.00201	CcSEcCtD
Maraviroc—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.0014	0.00477	CbGpPWpGaD
Maraviroc—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00139	0.00196	CcSEcCtD
Maraviroc—Hypersensitivity—Sorafenib—liver cancer	0.00139	0.00196	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00136	0.00465	CbGpPWpGaD
Maraviroc—Purpura—Doxorubicin—liver cancer	0.00136	0.00192	CcSEcCtD
Maraviroc—Asthenia—Sorafenib—liver cancer	0.00135	0.00191	CcSEcCtD
Maraviroc—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.00134	0.00456	CbGpPWpGaD
Maraviroc—Cerebrovascular accident—Doxorubicin—liver cancer	0.00134	0.00189	CcSEcCtD
Maraviroc—Pruritus—Sorafenib—liver cancer	0.00133	0.00188	CcSEcCtD
Maraviroc—Orthostatic hypotension—Epirubicin—liver cancer	0.00129	0.00183	CcSEcCtD
Maraviroc—Abdominal pain upper—Epirubicin—liver cancer	0.00129	0.00183	CcSEcCtD
Maraviroc—Diarrhoea—Sorafenib—liver cancer	0.00129	0.00182	CcSEcCtD
Maraviroc—CCR5—Disease—ALDOB—liver cancer	0.00129	0.00439	CbGpPWpGaD
Maraviroc—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.00128	0.00438	CbGpPWpGaD
Maraviroc—Breast disorder—Epirubicin—liver cancer	0.00128	0.00181	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00128	0.0018	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00128	0.0018	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SHC3—liver cancer	0.00127	0.00433	CbGpPWpGaD
Maraviroc—Nasopharyngitis—Epirubicin—liver cancer	0.00127	0.00179	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00125	0.00177	CcSEcCtD
Maraviroc—Dizziness—Sorafenib—liver cancer	0.00125	0.00176	CcSEcCtD
Maraviroc—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.00123	0.00421	CbGpPWpGaD
Maraviroc—Abdominal distension—Epirubicin—liver cancer	0.00123	0.00174	CcSEcCtD
Maraviroc—Influenza—Epirubicin—liver cancer	0.00122	0.00173	CcSEcCtD
Maraviroc—Eosinophilia—Epirubicin—liver cancer	0.00121	0.00171	CcSEcCtD
Maraviroc—Pancreatitis—Epirubicin—liver cancer	0.0012	0.0017	CcSEcCtD
Maraviroc—Vomiting—Sorafenib—liver cancer	0.0012	0.00169	CcSEcCtD
Maraviroc—Orthostatic hypotension—Doxorubicin—liver cancer	0.0012	0.00169	CcSEcCtD
Maraviroc—Abdominal pain upper—Doxorubicin—liver cancer	0.0012	0.00169	CcSEcCtD
Maraviroc—Angina pectoris—Epirubicin—liver cancer	0.00119	0.00169	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—F2—liver cancer	0.00119	0.00406	CbGpPWpGaD
Maraviroc—Rash—Sorafenib—liver cancer	0.00119	0.00168	CcSEcCtD
Maraviroc—Dermatitis—Sorafenib—liver cancer	0.00119	0.00168	CcSEcCtD
Maraviroc—Breast disorder—Doxorubicin—liver cancer	0.00118	0.00167	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00118	0.00167	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00118	0.00167	CcSEcCtD
Maraviroc—Headache—Sorafenib—liver cancer	0.00118	0.00167	CcSEcCtD
Maraviroc—Bronchitis—Epirubicin—liver cancer	0.00118	0.00167	CcSEcCtD
Maraviroc—Nasopharyngitis—Doxorubicin—liver cancer	0.00117	0.00166	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.00117	0.00399	CbGpPWpGaD
Maraviroc—Pancytopenia—Epirubicin—liver cancer	0.00116	0.00164	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00116	0.00163	CcSEcCtD
Maraviroc—Neutropenia—Epirubicin—liver cancer	0.00114	0.00162	CcSEcCtD
Maraviroc—Abdominal distension—Doxorubicin—liver cancer	0.00114	0.00161	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Epirubicin—liver cancer	0.00114	0.00161	CcSEcCtD
Maraviroc—Influenza—Doxorubicin—liver cancer	0.00113	0.0016	CcSEcCtD
Maraviroc—Eosinophilia—Doxorubicin—liver cancer	0.00112	0.00159	CcSEcCtD
Maraviroc—Nausea—Sorafenib—liver cancer	0.00112	0.00158	CcSEcCtD
Maraviroc—Pancreatitis—Doxorubicin—liver cancer	0.00111	0.00157	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.0011	0.00377	CbGpPWpGaD
Maraviroc—Angina pectoris—Doxorubicin—liver cancer	0.0011	0.00156	CcSEcCtD
Maraviroc—Pneumonia—Epirubicin—liver cancer	0.0011	0.00155	CcSEcCtD
Maraviroc—Infestation—Epirubicin—liver cancer	0.00109	0.00154	CcSEcCtD
Maraviroc—Infestation NOS—Epirubicin—liver cancer	0.00109	0.00154	CcSEcCtD
Maraviroc—Bronchitis—Doxorubicin—liver cancer	0.00109	0.00154	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00108	0.00153	CcSEcCtD
Maraviroc—Pancytopenia—Doxorubicin—liver cancer	0.00108	0.00152	CcSEcCtD
Maraviroc—Renal failure—Epirubicin—liver cancer	0.00107	0.00152	CcSEcCtD
Maraviroc—Neuropathy peripheral—Epirubicin—liver cancer	0.00107	0.00151	CcSEcCtD
Maraviroc—Jaundice—Epirubicin—liver cancer	0.00106	0.0015	CcSEcCtD
Maraviroc—Stomatitis—Epirubicin—liver cancer	0.00106	0.0015	CcSEcCtD
Maraviroc—Conjunctivitis—Epirubicin—liver cancer	0.00106	0.0015	CcSEcCtD
Maraviroc—Neutropenia—Doxorubicin—liver cancer	0.00106	0.0015	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00105	0.00149	CcSEcCtD
Maraviroc—Hepatobiliary disease—Epirubicin—liver cancer	0.00103	0.00146	CcSEcCtD
Maraviroc—Sinusitis—Epirubicin—liver cancer	0.00102	0.00145	CcSEcCtD
Maraviroc—Agranulocytosis—Epirubicin—liver cancer	0.00102	0.00144	CcSEcCtD
Maraviroc—CCR5—Disease—ADAM17—liver cancer	0.00102	0.00347	CbGpPWpGaD
Maraviroc—Pneumonia—Doxorubicin—liver cancer	0.00102	0.00144	CcSEcCtD
Maraviroc—Infestation—Doxorubicin—liver cancer	0.00101	0.00143	CcSEcCtD
Maraviroc—Infestation NOS—Doxorubicin—liver cancer	0.00101	0.00143	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—UGDH—liver cancer	0.001	0.00343	CbGpPWpGaD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.001	0.00142	CcSEcCtD
Maraviroc—Renal failure—Doxorubicin—liver cancer	0.000992	0.0014	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—liver cancer	0.00099	0.0014	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FST—liver cancer	0.000986	0.00336	CbGpPWpGaD
Maraviroc—Jaundice—Doxorubicin—liver cancer	0.000984	0.00139	CcSEcCtD
Maraviroc—Stomatitis—Doxorubicin—liver cancer	0.000984	0.00139	CcSEcCtD
Maraviroc—Rhinitis—Epirubicin—liver cancer	0.000982	0.00139	CcSEcCtD
Maraviroc—Conjunctivitis—Doxorubicin—liver cancer	0.000981	0.00139	CcSEcCtD
Maraviroc—Pharyngitis—Epirubicin—liver cancer	0.000972	0.00138	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PRKCE—liver cancer	0.000968	0.0033	CbGpPWpGaD
Maraviroc—Urinary tract disorder—Epirubicin—liver cancer	0.000967	0.00137	CcSEcCtD
Maraviroc—Connective tissue disorder—Epirubicin—liver cancer	0.000963	0.00136	CcSEcCtD
Maraviroc—Urethral disorder—Epirubicin—liver cancer	0.00096	0.00136	CcSEcCtD
Maraviroc—CCR5—Disease—PSMD10—liver cancer	0.000957	0.00327	CbGpPWpGaD
Maraviroc—CCR5—Disease—PSMA4—liver cancer	0.000957	0.00327	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Doxorubicin—liver cancer	0.000955	0.00135	CcSEcCtD
Maraviroc—Sinusitis—Doxorubicin—liver cancer	0.000947	0.00134	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—liver cancer	0.000942	0.00133	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TRIO—liver cancer	0.000941	0.00321	CbGpPWpGaD
Maraviroc—CCR5—Disease—GOT2—liver cancer	0.000931	0.00318	CbGpPWpGaD
Maraviroc—Erythema multiforme—Epirubicin—liver cancer	0.000926	0.00131	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000918	0.00313	CbGpPWpGaD
Maraviroc—Eye disorder—Epirubicin—liver cancer	0.000915	0.0013	CcSEcCtD
Maraviroc—Cardiac disorder—Epirubicin—liver cancer	0.000909	0.00129	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—liver cancer	0.000909	0.00129	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCR4—liver cancer	0.000902	0.00308	CbGpPWpGaD
Maraviroc—Pharyngitis—Doxorubicin—liver cancer	0.0009	0.00127	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—liver cancer	0.000895	0.00127	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—liver cancer	0.000891	0.00126	CcSEcCtD
Maraviroc—Angiopathy—Epirubicin—liver cancer	0.000889	0.00126	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—liver cancer	0.000888	0.00126	CcSEcCtD
Maraviroc—Mediastinal disorder—Epirubicin—liver cancer	0.000883	0.00125	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PRKCE—liver cancer	0.000879	0.003	CbGpPWpGaD
Maraviroc—Alopecia—Epirubicin—liver cancer	0.000866	0.00122	CcSEcCtD
Maraviroc—Mental disorder—Epirubicin—liver cancer	0.000858	0.00121	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—liver cancer	0.000857	0.00121	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CSF2—liver cancer	0.000857	0.00292	CbGpPWpGaD
Maraviroc—Malnutrition—Epirubicin—liver cancer	0.000853	0.00121	CcSEcCtD
Maraviroc—Erythema—Epirubicin—liver cancer	0.000853	0.00121	CcSEcCtD
Maraviroc—Eye disorder—Doxorubicin—liver cancer	0.000847	0.0012	CcSEcCtD
Maraviroc—Cardiac disorder—Doxorubicin—liver cancer	0.000841	0.00119	CcSEcCtD
Maraviroc—Flatulence—Epirubicin—liver cancer	0.00084	0.00119	CcSEcCtD
Maraviroc—Angiopathy—Doxorubicin—liver cancer	0.000822	0.00116	CcSEcCtD
Maraviroc—Mediastinal disorder—Doxorubicin—liver cancer	0.000817	0.00116	CcSEcCtD
Maraviroc—CCR5—Disease—GOT1—liver cancer	0.000804	0.00274	CbGpPWpGaD
Maraviroc—Alopecia—Doxorubicin—liver cancer	0.000801	0.00113	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—liver cancer	0.000794	0.00112	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—liver cancer	0.000789	0.00112	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—liver cancer	0.000789	0.00112	CcSEcCtD
Maraviroc—Anaemia—Epirubicin—liver cancer	0.000788	0.00111	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CSF2—liver cancer	0.000778	0.00265	CbGpPWpGaD
Maraviroc—Flatulence—Doxorubicin—liver cancer	0.000777	0.0011	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000768	0.00262	CbGpPWpGaD
Maraviroc—Syncope—Epirubicin—liver cancer	0.000765	0.00108	CcSEcCtD
Maraviroc—Leukopenia—Epirubicin—liver cancer	0.000763	0.00108	CcSEcCtD
Maraviroc—Loss of consciousness—Epirubicin—liver cancer	0.000749	0.00106	CcSEcCtD
Maraviroc—Cough—Epirubicin—liver cancer	0.000744	0.00105	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000742	0.00253	CbGpPWpGaD
Maraviroc—CCR5—Disease—PRKCE—liver cancer	0.000742	0.00253	CbGpPWpGaD
Maraviroc—Convulsion—Epirubicin—liver cancer	0.000739	0.00105	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000732	0.0025	CbGpPWpGaD
Maraviroc—Anaemia—Doxorubicin—liver cancer	0.000729	0.00103	CcSEcCtD
Maraviroc—Myalgia—Epirubicin—liver cancer	0.000726	0.00103	CcSEcCtD
Maraviroc—Anxiety—Epirubicin—liver cancer	0.000723	0.00102	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000721	0.00102	CcSEcCtD
Maraviroc—Discomfort—Epirubicin—liver cancer	0.000717	0.00101	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ADAM17—liver cancer	0.000713	0.00243	CbGpPWpGaD
Maraviroc—Syncope—Doxorubicin—liver cancer	0.000708	0.001	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—liver cancer	0.000706	0.000999	CcSEcCtD
Maraviroc—Oedema—Epirubicin—liver cancer	0.000696	0.000985	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—liver cancer	0.000693	0.000981	CcSEcCtD
Maraviroc—Infection—Epirubicin—liver cancer	0.000691	0.000978	CcSEcCtD
Maraviroc—Cough—Doxorubicin—liver cancer	0.000688	0.000974	CcSEcCtD
Maraviroc—Shock—Epirubicin—liver cancer	0.000685	0.000969	CcSEcCtD
Maraviroc—Convulsion—Doxorubicin—liver cancer	0.000684	0.000967	CcSEcCtD
Maraviroc—Nervous system disorder—Epirubicin—liver cancer	0.000682	0.000965	CcSEcCtD
Maraviroc—Skin disorder—Epirubicin—liver cancer	0.000676	0.000956	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—F2—liver cancer	0.000672	0.00229	CbGpPWpGaD
Maraviroc—Myalgia—Doxorubicin—liver cancer	0.000672	0.00095	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PSMD10—liver cancer	0.00067	0.00229	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PSMA4—liver cancer	0.00067	0.00229	CbGpPWpGaD
Maraviroc—Anxiety—Doxorubicin—liver cancer	0.000669	0.000947	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000667	0.000944	CcSEcCtD
Maraviroc—Discomfort—Doxorubicin—liver cancer	0.000664	0.000939	CcSEcCtD
Maraviroc—Anorexia—Epirubicin—liver cancer	0.000663	0.000938	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.00066	0.00225	CbGpPWpGaD
Maraviroc—CCR5—Disease—H2AFX—liver cancer	0.000647	0.00221	CbGpPWpGaD
Maraviroc—Oedema—Doxorubicin—liver cancer	0.000644	0.000911	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CG—liver cancer	0.000643	0.00219	CbGpPWpGaD
Maraviroc—Infection—Doxorubicin—liver cancer	0.00064	0.000905	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000635	0.00217	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000634	0.000897	CcSEcCtD
Maraviroc—Shock—Doxorubicin—liver cancer	0.000634	0.000896	CcSEcCtD
Maraviroc—Nervous system disorder—Doxorubicin—liver cancer	0.000631	0.000893	CcSEcCtD
Maraviroc—Insomnia—Epirubicin—liver cancer	0.000629	0.00089	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—liver cancer	0.000625	0.000885	CcSEcCtD
Maraviroc—Paraesthesia—Epirubicin—liver cancer	0.000625	0.000884	CcSEcCtD
Maraviroc—Anorexia—Doxorubicin—liver cancer	0.000614	0.000868	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—F2—liver cancer	0.00061	0.00208	CbGpPWpGaD
Maraviroc—Decreased appetite—Epirubicin—liver cancer	0.000605	0.000856	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000602	0.00205	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Epirubicin—liver cancer	0.000601	0.00085	CcSEcCtD
Maraviroc—Fatigue—Epirubicin—liver cancer	0.0006	0.000849	CcSEcCtD
Maraviroc—Constipation—Epirubicin—liver cancer	0.000595	0.000842	CcSEcCtD
Maraviroc—Pain—Epirubicin—liver cancer	0.000595	0.000842	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000587	0.002	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000587	0.00083	CcSEcCtD
Maraviroc—CCR5—Disease—MTHFR—liver cancer	0.000586	0.002	CbGpPWpGaD
Maraviroc—CCR5—Disease—TERT—liver cancer	0.000585	0.002	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CG—liver cancer	0.000584	0.00199	CbGpPWpGaD
Maraviroc—Insomnia—Doxorubicin—liver cancer	0.000582	0.000824	CcSEcCtD
Maraviroc—Paraesthesia—Doxorubicin—liver cancer	0.000578	0.000818	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000577	0.00197	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Epirubicin—liver cancer	0.000569	0.000805	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000569	0.00194	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CD—liver cancer	0.000565	0.00193	CbGpPWpGaD
Maraviroc—Decreased appetite—Doxorubicin—liver cancer	0.00056	0.000792	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000556	0.000786	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—liver cancer	0.000555	0.000785	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—liver cancer	0.000551	0.000779	CcSEcCtD
Maraviroc—Pain—Doxorubicin—liver cancer	0.000551	0.000779	CcSEcCtD
Maraviroc—Abdominal pain—Epirubicin—liver cancer	0.00055	0.000778	CcSEcCtD
Maraviroc—Body temperature increased—Epirubicin—liver cancer	0.00055	0.000778	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000533	0.00182	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000528	0.0018	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Doxorubicin—liver cancer	0.000527	0.000745	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000526	0.0018	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.00052	0.00177	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PRKCE—liver cancer	0.000519	0.00177	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000514	0.00175	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CD—liver cancer	0.000513	0.00175	CbGpPWpGaD
Maraviroc—Hypersensitivity—Epirubicin—liver cancer	0.000513	0.000725	CcSEcCtD
Maraviroc—Abdominal pain—Doxorubicin—liver cancer	0.000509	0.00072	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—liver cancer	0.000509	0.00072	CcSEcCtD
Maraviroc—Asthenia—Epirubicin—liver cancer	0.000499	0.000706	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000496	0.00169	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CB—liver cancer	0.000493	0.00168	CbGpPWpGaD
Maraviroc—CCR5—Disease—APC—liver cancer	0.000493	0.00168	CbGpPWpGaD
Maraviroc—Pruritus—Epirubicin—liver cancer	0.000492	0.000697	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IGF2—liver cancer	0.000492	0.00168	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—NAT2—liver cancer	0.00049	0.00167	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000484	0.00165	CbGpPWpGaD
Maraviroc—Diarrhoea—Epirubicin—liver cancer	0.000476	0.000674	CcSEcCtD
Maraviroc—Hypersensitivity—Doxorubicin—liver cancer	0.000474	0.000671	CcSEcCtD
Maraviroc—CCR5—Disease—BRAF—liver cancer	0.000463	0.00158	CbGpPWpGaD
Maraviroc—Asthenia—Doxorubicin—liver cancer	0.000462	0.000654	CcSEcCtD
Maraviroc—Dizziness—Epirubicin—liver cancer	0.00046	0.000651	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CSF2—liver cancer	0.000459	0.00157	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—RAF1—liver cancer	0.000458	0.00156	CbGpPWpGaD
Maraviroc—Pruritus—Doxorubicin—liver cancer	0.000456	0.000644	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—H2AFX—liver cancer	0.000453	0.00154	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2—liver cancer	0.000453	0.00154	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CB—liver cancer	0.000448	0.00153	CbGpPWpGaD
Maraviroc—Vomiting—Epirubicin—liver cancer	0.000442	0.000626	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—liver cancer	0.000441	0.000623	CcSEcCtD
Maraviroc—Rash—Epirubicin—liver cancer	0.000439	0.000621	CcSEcCtD
Maraviroc—Dermatitis—Epirubicin—liver cancer	0.000438	0.00062	CcSEcCtD
Maraviroc—Headache—Epirubicin—liver cancer	0.000436	0.000617	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CD—liver cancer	0.000433	0.00148	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000432	0.00147	CbGpPWpGaD
Maraviroc—CCR5—Disease—SERPINE1—liver cancer	0.000428	0.00146	CbGpPWpGaD
Maraviroc—Dizziness—Doxorubicin—liver cancer	0.000426	0.000602	CcSEcCtD
Maraviroc—Nausea—Epirubicin—liver cancer	0.000413	0.000585	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000411	0.0014	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2—liver cancer	0.000411	0.0014	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TERT—liver cancer	0.00041	0.0014	CbGpPWpGaD
Maraviroc—Vomiting—Doxorubicin—liver cancer	0.000409	0.000579	CcSEcCtD
Maraviroc—Rash—Doxorubicin—liver cancer	0.000406	0.000574	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—liver cancer	0.000406	0.000574	CcSEcCtD
Maraviroc—Headache—Doxorubicin—liver cancer	0.000403	0.000571	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000392	0.00134	CbGpPWpGaD
Maraviroc—CCR5—Disease—RAF1—liver cancer	0.000387	0.00132	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—liver cancer	0.000382	0.000541	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CB—liver cancer	0.000378	0.00129	CbGpPWpGaD
Maraviroc—CCR5—Disease—MTOR—liver cancer	0.000378	0.00129	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KDR—liver cancer	0.000375	0.00128	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK14—liver cancer	0.000372	0.00127	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ESR1—liver cancer	0.000365	0.00125	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—F2—liver cancer	0.000361	0.00123	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN1B—liver cancer	0.000354	0.00121	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APC—liver cancer	0.000345	0.00118	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—liver cancer	0.000345	0.00118	CbGpPWpGaD
Maraviroc—CCR5—Disease—CTNNB1—liver cancer	0.000335	0.00114	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN1A—liver cancer	0.000327	0.00112	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BRAF—liver cancer	0.000324	0.00111	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.00032	0.00109	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000315	0.00108	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CD—liver cancer	0.000303	0.00103	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—liver cancer	0.0003	0.00102	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SERPINE1—liver cancer	0.0003	0.00102	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—KRAS—liver cancer	0.000297	0.00101	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000293	0.001	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT3—liver cancer	0.000292	0.000995	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—liver cancer	0.000273	0.000931	CbGpPWpGaD
Maraviroc—CCR5—Disease—MYC—liver cancer	0.000271	0.000925	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RAF1—liver cancer	0.000271	0.000924	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—liver cancer	0.00027	0.000923	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MTOR—liver cancer	0.000264	0.000902	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CB—liver cancer	0.000264	0.000902	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000264	0.000899	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.00026	0.000887	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—liver cancer	0.000252	0.000861	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—liver cancer	0.000251	0.000855	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1B—liver cancer	0.000248	0.000846	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—liver cancer	0.000245	0.000837	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP3—liver cancer	0.000243	0.00083	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—liver cancer	0.000243	0.000828	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000242	0.000826	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—liver cancer	0.000242	0.000824	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000239	0.000815	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCND1—liver cancer	0.000237	0.000808	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JUN—liver cancer	0.000236	0.000806	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CTNNB1—liver cancer	0.000234	0.0008	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CA—liver cancer	0.00023	0.000785	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—liver cancer	0.00023	0.000784	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.00023	0.000783	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1A—liver cancer	0.000229	0.000781	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000226	0.000773	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK8—liver cancer	0.000224	0.000762	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT1—liver cancer	0.000223	0.00076	CbGpPWpGaD
Maraviroc—CCR5—Disease—HRAS—liver cancer	0.000213	0.000726	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFA—liver cancer	0.000206	0.000704	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT3—liver cancer	0.000204	0.000697	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—liver cancer	0.000204	0.000695	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MYC—liver cancer	0.00019	0.000648	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—liver cancer	0.000189	0.000646	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT1—liver cancer	0.000188	0.000641	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KRAS—liver cancer	0.000175	0.000598	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UGDH—liver cancer	0.000172	0.000586	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—EPT1—liver cancer	0.000161	0.000551	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—liver cancer	0.000161	0.00055	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—liver cancer	0.000156	0.000532	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TAT—liver cancer	0.000153	0.000522	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HRAS—liver cancer	0.000149	0.000509	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—liver cancer	0.000143	0.000487	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—liver cancer	0.000132	0.000449	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CPT1B—liver cancer	0.000104	0.000355	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GLUL—liver cancer	0.000104	0.000355	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NR1H4—liver cancer	0.0001	0.000342	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA3—liver cancer	9.86e-05	0.000336	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA4—liver cancer	9.02e-05	0.000308	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA2—liver cancer	8.79e-05	0.0003	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA1—liver cancer	8.48e-05	0.000289	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAT2—liver cancer	8.39e-05	0.000286	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDOB—liver cancer	8.04e-05	0.000274	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CRABP1—liver cancer	7.67e-05	0.000262	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPGDS—liver cancer	6.7e-05	0.000229	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PSMA4—liver cancer	5.98e-05	0.000204	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PSMD10—liver cancer	5.98e-05	0.000204	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GOT2—liver cancer	5.81e-05	0.000198	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2E1—liver cancer	5.47e-05	0.000186	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYCS—liver cancer	5.11e-05	0.000174	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GGT1—liver cancer	5.02e-05	0.000171	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GOT1—liver cancer	5.02e-05	0.000171	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—liver cancer	4.51e-05	0.000154	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMOX1—liver cancer	4.45e-05	0.000152	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—liver cancer	4.14e-05	0.000141	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1A1—liver cancer	3.93e-05	0.000134	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTHFR—liver cancer	3.66e-05	0.000125	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARA—liver cancer	3.59e-05	0.000123	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—liver cancer	3.08e-05	0.000105	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARG—liver cancer	2.97e-05	0.000101	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CD—liver cancer	2.7e-05	9.22e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—liver cancer	2.67e-05	9.11e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CB—liver cancer	2.36e-05	8.04e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—liver cancer	1.44e-05	4.9e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—liver cancer	1.17e-05	4e-05	CbGpPWpGaD
